Pharmacokinetics and Pharmacodynamics

Key Points

• Pharmacokinetics describes four sequential stages a drug undergoes in the body: absorption, distribution, metabolism, and excretion (ADME).
• Absorption moves a drug from the administration site into systemic circulation; distribution spreads it throughout body tissues.
• Metabolism breaks down the drug molecule; excretion eliminates the drug and its byproducts from the body.
• Pharmacodynamics describes what drugs do to the body — drugs bind to receptor sites via a lock-and-key mechanism; binding strength is called affinity, and the resulting drug availability is bioavailability.
• Agonists bind to a receptor and activate it to produce a desired effect; antagonists compete for the same receptor site and block the agonist’s action.
• Potency refers to the amount of drug required to produce the desired effect — a highly potent drug achieves therapeutic effect at a low dose; a low-potency drug requires a higher dose for the same effect.
• Selectivity refers to how specifically a drug targets its intended receptor — selective drugs produce fewer unintended effects; nonselective drugs affect multiple receptor types and increase the risk of side effects.
• Side effects are known, anticipated unintended effects (e.g., nausea, drowsiness); adverse effects are unpredictable, serious, and are grounds for drug discontinuation.
• Pharmacogenetics explains why individual responses to the same drug and dose vary — a person’s unique genetic makeup significantly impacts drug response.

Pathophysiology

Pharmacokinetics is the study of how the body handles a drug across four stages, abbreviated ADME:

• Absorption — drug enters the body from the administration site and travels into systemic circulation.
• Distribution — drug spreads from circulation throughout body tissues.
• Metabolism — drug molecule is broken down (primarily by the liver).
• Excretion — drug and its metabolites are eliminated from the body (primarily via kidneys).

Because drugs cannot be directly visualized in the body, pharmacokinetic scientists rely on mathematical models and precise blood and urine measurements to track where a drug goes and how much remains after processing. Principles of chemistry explain the interactions between drugs and biological environments (for example bloodstream and cell membranes), which determine how much of a drug is ultimately absorbed and active.

Pharmacodynamics describes the effects of drugs in the body and the mechanisms by which they act — the mechanism of action of a drug describes exactly how it produces its pharmacologic effect. A drug’s mechanism may involve:

• Receptor binding: Many drugs bind to specific receptors on the surface of cells. For example, morphine binds to opioid receptors and inhibits pain signal transmission; beta-blockers bind to beta-adrenergic receptors on cardiac cells.
• Enzyme inhibition: Some drugs block specific enzymes to produce their effect. For example, monoamine oxidase inhibitors (MAOIs) block the enzyme that breaks down serotonin and dopamine, increasing CNS concentrations of these neurotransmitters.
• Non-receptor mechanisms: Some drugs act by physical or chemical means rather than receptor binding. For example, magnesium citrate (osmotic laxative) attracts water into the bowel, softening stool — its mechanism requires no receptor.

As a drug travels through the bloodstream, it demonstrates affinity for specific receptor sites — the strength with which it binds. Drug-receptor interaction follows a lock-and-key system: structural compatibility between drug and receptor determines binding and pharmacologic effect. This receptor binding determines bioavailability — the presence and activity of the drug in circulation.

Agonists and Antagonists

Drugs that act at receptor sites are classified by their effect on the receptor:

• Agonist: Binds tightly to a receptor and activates it, producing the intended pharmacologic effect. Example: morphine (opioid agonist → activates opioid receptors → pain relief).
• Antagonist: Competes with agonists for the same receptor site and blocks activation of the receptor, preventing the usual pharmacologic response. Example: atenolol (beta-blocker → antagonist at beta-adrenergic receptors → reduces heart rate and blood pressure by blocking sympathetic stimulation).

Understanding whether a drug is an agonist or antagonist determines the clinical response: prescribers may intentionally use an antagonist to reverse an agonist’s effect (for example, naloxone as an opioid antagonist to reverse opioid toxicity).

Potency and Selectivity

When evaluating a drug’s pharmacodynamic profile, nurses consider two additional properties:

• Potency: The amount of drug required to produce the desired therapeutic effect. A highly potent drug achieves the therapeutic effect at a smaller dose; a low-potency drug requires a larger dose to produce the same effect. Example: opioid analgesics have high potency — a small dose produces significant pain relief. Nurses verify that all doses fall within the safe dosage range for the patient’s current status.
• Selectivity: The degree to which a drug targets its intended receptor vs. affecting other receptor types. Selective drugs bind preferentially to specific target sites; nonselective drugs interact with multiple receptor types, increasing the likelihood of unintended effects. Example: selective beta-1 blockers (e.g., metoprolol) act primarily on cardiac beta-1 receptors, whereas nonselective beta-blockers affect both beta-1 (heart) and beta-2 (lungs) receptors — causing respiratory side effects (e.g., bronchospasm) in susceptible patients.

Side Effects and Adverse Effects

Drug administration can produce effects beyond the intended therapeutic action:

• Side effect: A drug effect other than the intended therapeutic effect. Side effects are generally anticipated and documented as known consequences of the drug. Examples: nausea, vomiting, diarrhea, and drowsiness. In some cases, a side effect may be exploited clinically — for example, the drowsiness caused by hydrocodone (an opioid) may benefit a patient who has difficulty sleeping due to pain.
• Adverse effect: An unpredictable, serious, and potentially harmful drug response. Adverse effects are typically severe enough to warrant discontinuing the medication. Example: ciprofloxacin (fluoroquinolone antibiotic) → tendon rupture. Adverse effects must be reported to the pharmacy and tracked as a patient safety concern per facility policy.

Pharmacogenetics recognizes that individual genetic variation significantly impacts drug response. Although many responses can be anticipated based on population pharmacokinetics, a person’s unique genetic makeup can substantially alter how they respond to a given drug.

Classification

• Absorption: Drug entry from the administration site into systemic bloodstream.
• Distribution: Spread of drug from bloodstream to body tissues and target organs.
• Metabolism: Enzymatic breakdown of the drug molecule into metabolites.
• Excretion: Elimination of drug and metabolites from the body.
• Receptor affinity: Strength of drug–receptor binding; determines intensity of pharmacodynamic effect.
• Lock-and-key system: Structural compatibility model of drug–receptor interaction.
• Bioavailability: The proportion of drug that reaches systemic circulation in an active form.
• Agonist: Drug that binds to and activates a receptor, producing a pharmacologic effect.
• Antagonist: Drug that binds to a receptor and blocks activation, preventing or reversing an agonist’s effect.
• Mechanism of action: The specific process by which a drug produces its pharmacologic effect (receptor binding, enzyme inhibition, or physical/chemical action).
• Potency: Amount of drug required to achieve the desired effect; high potency = minimal dose needed.
• Selectivity: Specificity of a drug for its target receptor; selective = fewer unintended effects; nonselective = higher risk of side effects at non-target sites.
• Side effect: Known, anticipated, unintended drug effect; may occasionally be beneficial.
• Adverse effect: Unpredictable, harmful drug response; grounds for discontinuation; must be reported and tracked.
• Pharmacogenetics: Study of how genetic makeup influences an individual’s drug response.

Nursing Assessment

NCLEX Focus

Identify which ADME stage explains a clinical observation — for example delayed onset (poor absorption), prolonged effect (impaired metabolism or excretion), or variable response (pharmacogenetics). Know the agonist vs. antagonist distinction and be able to identify clinical examples of each.

• Assess the route of drug administration and expected absorption timing relative to clinical effect.
• Assess organ function relevant to pharmacokinetics: renal function affects excretion; hepatic function affects metabolism.
• Assess patient age — older adults typically have slower metabolism and reduced renal excretion, increasing drug accumulation risk.
• Assess concurrent medications for potential pharmacokinetic interactions.
• Assess whether a drug is an agonist or antagonist — this determines the expected clinical response and whether reversal agents are available (e.g., naloxone for opioid agonist overdose).
• Assess drug selectivity profile: nonselective drugs carry higher risk of off-target side effects. Monitor accordingly (e.g., nonselective beta-blockers → assess for respiratory side effects).
• Distinguish anticipated side effects (educate patient and monitor) from adverse effects (assess severity, consider withholding and notifying prescriber, report to pharmacy per policy).
• Assess for unexpected drug responses that may reflect individual pharmacogenetic variation.

Nursing Interventions

• Administer medications by the prescribed route only; route changes alter absorption and pharmacokinetics.
• Time drug administration relative to food or other medications as specified, since these factors affect absorption.
• Monitor for signs of drug accumulation (toxicity) in patients with impaired renal or hepatic function.
• Educate patients that individual responses to medications vary and that prescribers may need to adjust doses based on their personal response.
• When a patient reports a new or unexpected effect: determine whether it is a known side effect (monitor, educate, reassure if tolerable) or a potentially serious adverse effect (withhold drug, notify prescriber, document, report to pharmacy per agency policy).
• Verify all drug doses are within the recommended safe dosage range for the patient’s current status, taking potency and weight into account.

Organ Impairment and Drug Accumulation

Impaired metabolism (hepatic dysfunction) or impaired excretion (renal dysfunction) can cause drug accumulation and toxicity even at standard doses. Enhanced monitoring and dose adjustment are essential.

Pharmacology

Pharmacokinetic Stage	Clinical Relevance	Nursing Implication
Absorption	Route determines speed and completeness of drug entry	IV administration produces the fastest onset; oral is subject to GI and hepatic factors
Distribution	Drug spreads to tissues based on blood flow and solubility	Target-organ effects depend on distribution reaching the site of action
Metabolism	Liver breaks down most drugs	Hepatic impairment slows metabolism and raises drug levels
Excretion	Kidneys eliminate most drug metabolites	Renal impairment delays elimination and increases toxicity risk

Clinical Judgment Application

Clinical Scenario

A patient prescribed an oral analgesic reports that the medication “doesn’t seem to work as well” as when they received the same drug intravenously after surgery.

• Recognize Cues: Reduced effectiveness of oral versus IV formulation of the same drug.
• Analyze Cues: Oral drugs undergo absorption through the GI tract and initial hepatic metabolism before reaching systemic circulation, reducing the amount of active drug available (lower bioavailability) compared to IV.
• Prioritize Hypotheses: Route-dependent difference in bioavailability is the most likely explanation.
• Generate Solutions: Clarify that oral doses are often prescribed higher than IV doses to account for lower bioavailability; report persistent inadequate pain relief for prescriber reassessment.
• Take Action: Document patient’s report, reassess pain, and notify prescriber if inadequate relief continues.
• Evaluate Outcomes: Pain is adequately managed with an adjusted approach; patient understands why route affects drug effect.

Related Concepts

• medication-dosing-systems-calculation-and-therapeutic-monitoring — Dosage calculation and therapeutic monitoring build on pharmacokinetic principles.
• medication-administration-safety-measures — Safe administration practices account for pharmacokinetic variability by route and patient factors.
• drug-interactions — Many drug interactions occur by altering pharmacokinetics (absorption, metabolism, or excretion) of co-administered drugs.

Self-Check

1. Name the four stages of pharmacokinetics in order.
2. A patient with kidney disease is prescribed a renally excreted antibiotic. Which pharmacokinetic stage is most affected, and what is the clinical risk?
3. Two patients receive the same opioid dose and have very different pain relief outcomes. How does pharmacogenetics explain this variation?
4. A patient receives naloxone after a morphine overdose. Is naloxone an agonist or antagonist at the opioid receptor? What clinical effect does this produce?
5. A patient receiving ciprofloxacin reports severe right heel pain. What type of drug effect is this, and what action should the nurse take?
6. Metoprolol is described as a selective beta-1 blocker, while propranolol is nonselective. What additional side effect risk does propranolol carry that metoprolol does not?